¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡´Â 121¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2034³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 9.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦´Â ÇǺÎÀÇ ¿°Áõ, °¡·Á¿òÁõ, °ÇÁ¶ÇÔÀ» °ü¸®Çϰí, Áõ»óÀÇ À翬À» ¾ïÁ¦Çϸç, Áõ»óÀ» Á¶ÀýÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¿¡´Â ¿Ü¿ë¾à, Àü½Å¿ä¹ý, »ý¹°ÇÐÀû Á¦Á¦ µîÀÌ ÀÖÀ¸¸ç ÁúȯÀÇ ÁßÁõµµ¿¡ µû¶ó ¼±Åõ˴ϴÙ. ¾ÆÅäÇÇ ÇǺο°ÀÇ À¯º´·ü »ó½Â, °·ÂÇÑ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎ, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚÀÇ Áõ°¡°¡ ½ÃÀå °³Ã´¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ±â¾÷Àº ½ÅÁ¦Ç°À» Ãâ½ÃÇϰí ÀÖÀ¸¸ç, ÀÓ»ó ½ÃÇèÀÇ ¾çÈ£ÇÑ °á°ú°¡ ¼öÀÍ È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
2023³â ¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 111¾ï ´Þ·¯¿´À¸¸ç, 2024³â¿¡´Â »ý¹°ÇÐÀû Á¦Á¦°¡ 41.3%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¿© ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¼ö¿ä´Â, ±× ¶Ù¾î³ Ä¡·á ¼ºÀû ¹× Á¦Ç° Àΰ¡ÀÇ Áõ°¡¿¡ ÀÇÇØ »ó½ÂÀ» °è¼ÓÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 121¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 310¾ï ´Þ·¯ |
CAGR | 9.9% |
Åõ¿© °æ·Îº°·Î ½ÃÀåÀº ÁÖ»çÁ¦, ¿Ü¿ëÁ¦, °æ±¸Á¦·Î ³ª´¹´Ï´Ù. 2024³â ¸ÅÃâ Á¡À¯À²Àº ÁÖ»çÁ¦°¡ 45.1%·Î ¿ìÀ§¸¦ Â÷ÁöÇß½À´Ï´Ù. IL-4, IL-13, JAK ¾ïÁ¦Á¦ µî ¿°Áõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î »ý¹°ÇÐÀû Á¦Á¦ÀÇ Áֻ簡 Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ¸·Î Á¦Ç°ÀÇ »ó½Ã°¡ °¡¼ÓȵǾî ÁÖ¿ä ½ÃÀå¿¡¼ÀÇ Á¢±Ù¼º°ú ä¿ë·üÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ȯÀÚÃþº° ºÎ¹®¿¡´Â ¼Ò¾Æ¿Í ¼ºÀÎ Ä«Å×°í¸®°¡ ÀÖ½À´Ï´Ù. ÁÖ·Î ¼Ò¾Æ¿¡¼ ¾ÆÅäÇÇ ÇǺο°ÀÇ ÀÌȯÀ²ÀÌ ³ô±â ¶§¹®¿¡ 2024³â ¸ÅÃâÀº ¼Ò¾Æ ºÎ¹®ÀÌ 87¾ï ´Þ·¯·Î ÃÖ°í¿´½À´Ï´Ù. ¼Ò¾Æ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â ±ÔÁ¦ ´ç±¹ÀÌ Àú ¿¬·É ȯÀÚ¸¦ À§ÇØ Á¶Á¤µÈ ´õ ¸¹Àº Ä¡·á¹ýÀ» ½ÂÀÎÇÔ¿¡ µû¶ó Áõ°¡ÀÇ ±æÀ» µû¸¨´Ï´Ù. ¼Ò¾Æ¿ëÀ¸·Î Ưº°È÷ ¼³°èµÈ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ½Å¼ÓÇÑ ½ÂÀÎÀº ½ÃÀå È®´ë¸¦ ´õ¿í °ÈÇϰí ÀÖ½À´Ï´Ù.
À¯Åë ä³Î¿¡´Â º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ÀüÀÚ»ó°Å·¡ µîÀÌ ÀÖ½À´Ï´Ù. º´¿ø ¾à±¹Àº 2024³â 58¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¾à±¹Àº Àü¹®ÀûÀÎ Ä¡·á ¹× Àü½Å Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ¸¦ °ü¸®Çϰí Ä¡·á °á°ú¿Í ÀáÀçÀû ºÎÀÛ¿ëÀ» ÀûÀýÇÏ°Ô ¸ð´ÏÅ͸µÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.
¹Ì±¹ ½ÃÀåÀº »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖÀ¸¸ç ¸ÅÃâ¾×Àº 2023³â 47¾ï ´Þ·¯¿¡¼ 2034³â 131¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÎÁöµµ Çâ»ó¿¡ ´ëÇÑ ³ë·Â°ú ±¤°í Ȱµ¿ÀÇ È°¼ºÈ´Â ¿¬±¸ ÀÚ±ÝÀ» °ÈÇÏ°í °í±Þ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ È¯ÀÚ Á¢±ÙÀ» Çâ»ó½Ãŵ´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº ƯÈ÷ ÁßÁõ »ç·Ê¿Í ¼Ò¾Æ ȯÀÚ¿¡ ´ëÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ½ÂÀÎÀ» °è¼ÓÇØ¼ ºü¸£°Ô ÁøÇàÇϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ´õ¿í °ÈÇϰí ÀÖ½À´Ï´Ù.
The Global Atopic Dermatitis Drugs Market was valued at USD 12.1 billion in 2024 and is projected to grow at a 9.9% CAGR from 2025 to 2034. Atopic dermatitis drugs help manage skin inflammation, itching, and dryness, targeting flare-ups and controlling the condition. These treatments include topical medications, systemic therapies, and biologics, chosen based on disease severity. The rising prevalence of atopic dermatitis, strong drug pipelines, and increased investment in research and development are fueling market growth. Pharmaceutical companies are launching new products, and positive clinical trial results are driving revenue expansion.
In 2023, the atopic dermatitis drugs market was worth USD 11.1 billion. The biologics segment led the market in 2024, holding a 41.3% revenue share, driven by higher efficacy and long-term symptom control. The demand for biologics continues to rise due to their superior treatment outcomes and growing product approvals.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $12.1 Billion |
Forecast Value | $31 Billion |
CAGR | 9.9% |
By route of administration, the market is divided into injectable, topical, and oral treatments. The injectable segment dominated in 2024 with a 45.1% revenue share. New biologic injections targeting inflammatory pathways, such as IL-4, IL-13, and JAK inhibitors, are expanding treatment options. Regulatory approvals have accelerated product launches, increasing accessibility and adoption rates in major markets.
The patient demographic segmentation includes pediatric and adult categories. The pediatric segment led with USD 8.7 billion in revenue in 2024, primarily due to the high incidence of atopic dermatitis in children. The demand for pediatric therapies continues to grow as regulatory bodies approve more treatments tailored for younger patients. Expedited approvals for biologic formulations specifically designed for pediatric use are further driving market expansion.
Distribution channels include hospital pharmacies, retail pharmacies, and e-commerce. Hospital pharmacies accounted for USD 5.8 billion in revenue in 2024. These pharmacies play a crucial role in managing patients who require specialized or systemic treatments, ensuring proper monitoring of therapy outcomes and potential side effects.
The U.S. market has witnessed significant growth, with revenue rising from USD 4.7 billion in 2023 to a projected USD 13.1 billion by 2034. Increased awareness efforts and advocacy initiatives are enhancing research funding and improving patient access to advanced treatment options. Regulatory agencies continue to fast-track the approval of biologics, particularly for severe cases and pediatric patients, further supporting market growth.